Meeting of the ALAMEDA Consortium entitled: “Technologies and Artificial Intelligence (AI) for the Monitoring of Brain Diseases: The paradigm of Parkinson’s Disease”

The EU H2020 Project ALAMEDA (https://alamedaproject.eu/) aims primarily to design and validate an innovative model for collecting, acquiring, and analyzing clinical data and patient-generated and/or self-reported data using sensors, mobile applications, and artificial intelligence. This model will enable continuous monitoring of neurological disease progression and treatment response, as well as accurately predict disease evolution and potential relapses. The diseases selected for testing the developed methods and technologies are multiple sclerosis, Parkinson’s disease, and stroke.

The project, set to conclude at the end of 2023, has brought together cross-disciplinary and complementary skills from various European countries, from neurology to data engineering and artificial intelligence, to the design and development of apps and sensors, scientific communication, and the active involvement of patients and healthcare professionals through participatory research methods.

The present workshop, organized by the National and Kapodistrian University of Ahens (NKUA) and the First Department of Neurology, the site for the pilot study on Parkinson’s Disease, focusing on the contribution of Greek partners in the Parkinson’s Disease pilot project of ALAMEDA, will take place in the afternoon-evening (17:00-19:00) of Tuesday, December 5 2023, at Eginitio Hospital, in Athens (and online at: Zoom Meeting https://us02web.zoom.us/j/87256737316?pwd=bzBUNHBWR1pwR0Z4ZnBBSktXKzJWdz09). It aims to provide an overview of the results obtained from the ALAMEDA project and explore possible public-private synergies and collaborations with other complementary Greek initiatives and with the main players in the related industry at the regional Greek level.

The goal is to establish synergies with Greek stakeholders interested in researching and validating accurate and reliable digital measures that can be adopted on a large scale for monitoring Parkinson’s Disease and its progression and to provide useful information for predicting the course of the disease, thus allowing for more effective personalization of therapies. There will be an additional brief virtual presentation by FISM (Italian Multiple Sclerosis Society Foundation) to give the Italian Multiple Sclerosis perspective of participation in ALAMEDA.

Participation is free. A tentative Program is provided below.

Introduction, L. Stefanis, NKUA
ALAMEDA: The general project, P. Tsakanikas, ICCS
Designing the PD pilot, N. Bougea, NKUA
Running the PD pilot, N. Papagiannakis, NKUA
Patient satisfaction, N. Bougea and PD patient, NKUA
Feedback-initiated modification of the ALAMEDA protocol, N. Papagiannakis, NKUA
Patient dashboard, P. Tsakanikas, ICCS
Socio-economic factors, E. Panagiotounakou, NKUA
Sleep studies: The concept, A. Simitsi, NKUA
Sleep studies: Correlation with polysomnography, K. Lourentzos, NKUA
Unobtrusive recording of sleep position and movement data, G. Koutalieris, ENORA
The autonomic nervous system in the ALAMEDA PD pilot, A. Simitsi, NKUA
Initial results and roadmap to pending analyses, N. Papagiannakis, NKUA
The MS experience in ALAMEDA, Ludovico Pedulla and MS patient, FISM
Wrap-up, L. Stefanis, NKUA and P. Tsakanikas, ICCS